Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study

• Published in: Journal of endocrinological investigation Vol. 43; no. 10; pp. 1473 - 1483
• Main Authors: Bai, X., Chen, X., Wu, X., Huang, Y., Zhuang, Y., Chen, Y., Feng, C., Lin, Xiahong
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.10.2020; Springer Nature B.V
• Subjects: CTLA-4 protein; Diabetes; Diabetes insipidus; Diabetes mellitus; Endocrine disorders; Endocrinology; Hypopituitarism; Immune checkpoint inhibitors; Immunotherapy; Internal Medicine; Medicine; Medicine & Public Health; Metabolic Diseases; Monoclonal antibodies; Original Article; PD-1 protein; PD-L1 protein; Pituitary; Thyroid; Pituitary enlargement; Immune checkpoint inhibitor; Hypopituitarism; Adverse events; Hypophysitis

Purpose The aim of this study was to identify and characterize immune checkpoint inhibitors (ICIs)-associated pituitary adverse events (AEs). Methods This is a retrospective disproportionality study based on VigiBase, the World Health Organization (WHO) global database of individual case safety repo...